A Randomised, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 18-45 Years
Latest Information Update: 08 Jan 2025
At a glance
- Drugs Human papillomavirus recombinant vaccine nonavalent - Shanghai Bovax Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Shanghai Bovax Biotechnology
Most Recent Events
- 06 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 13 Aug 2024 Status changed from not yet recruiting to recruiting.
- 17 Jun 2024 New trial record